Clinical Trials Logo
  1. Home
  2. Malignant Solid Neoplasm
  3. NCT05496972
  4. Details
NCT05496972 Clinical Trial

Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology

Malignant Solid Neoplasm Clinical Trial

Official title:
Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05496972
Other study ID # 2020-1063
Secondary ID NCI-2021-09908
Status Recruiting
Phase
First received
Last updated
Start date April 21, 2021
Est. completion date July 1, 2027

Study information
Verified date March 2024
Source M.D. Anderson Cancer Center
Contact Chenyang Wang, MD
Phone (832) 710-1570
Email cwang23@mdanderson.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To understand more about the opinions of patients and health providers on the use of telemedicine in radiation oncology.

Description:

Primary Objective: To characterize patient and provider satisfaction with telemedicine in RO Secondary Objective: - To provide evidence for or against the use of telemedicine in radiation oncology (RO) - To assess the feasibility of and value added by telemedicine in RO - To describe barriers and facilitators to telemedicine in RO - To identify preferred use cases for telemedicine in RO

Recruitment information / eligibility
Status Recruiting
Enrollment 200
Est. completion date July 1, 2027
Est. primary completion date July 1, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients will be eligible if they are aged 18 or older and have undergone at least 1 telemedicine encounter (video visit) with the radiation oncology department at MD Anderson or its affiliates within 2 months from the initiation of the study (and prospectively as the study enrolls). This would include weekly see visits, follow-up visits, or consultations - English speaking - Access to email and internet to complete the survey - Attending physicians in the radiation oncology department who have utilized telemedicine will be contacted to fill out surveys reflecting their experience Exclusion Criteria: • Protected populations such as adults unable to consent, pregnant women, prisoners, and individuals who are not yet adults will be excluded

Study Design

Related Conditions & MeSH terms

Intervention

Behavioral:
• Survey Administration
Patients and providers complete survey over 10 minutes about their perspectives on the use of telemedicine

Locations
Country Name City State
United States MD Anderson Cancer Center Houston Texas

Sponsors (1)
Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Patient satisfaction survey with telemedicine in radiation oncology (RO) Sensitivity analyses will be performed with those rating 9 or higher or less than 9, and for those who "agree" or "strongly agree" with whether they are satisfied with telemedicine compared to those who give other answers. through study completion and average of one year.
Primary Provider satisfaction survey with telemedicine in radiation oncology (RO) Sensitivity analyses will be performed with those rating 9 or higher or less than 9, and for those who "agree" or "strongly agree" with whether they are satisfied with telemedicine compared to those who give other answers. through study completion and average of one year.
See also
  Status Clinical Trial Phase
Recruiting NCT06030427 - Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Suspended NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Recruiting NCT06192875 - A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
Completed NCT04122118 - Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor N/A
Active, not recruiting NCT04940299 - Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Phase 2
Active, not recruiting NCT03168737 - 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients Phase 1
Active, not recruiting NCT06062901 - An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors N/A
Active, not recruiting NCT02444741 - Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT04081298 - eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors N/A
Active, not recruiting NCT04555837 - Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Phase 1/Phase 2
Completed NCT04983901 - PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN Phase 2
Active, not recruiting NCT04602026 - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer N/A
Recruiting NCT04871542 - Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Recruiting NCT04592250 - Financial Toxicity in Cancer Patients
Recruiting NCT05112614 - Role of Gut Microbiome in Cancer Therapy
Active, not recruiting NCT04296305 - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain Phase 4
Recruiting NCT05873608 - Communication Issues in Patient and Provider Discussions of Immunotherapy N/A
Recruiting NCT02464696 - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure N/A
Recruiting NCT05372614 - Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene Phase 1

External Links